Text Size
Santen Global

2024 Press Release

RSS

Press Release

Santen applies for manufacturing and marketing approval in Japan for STN1012600 ophthalmic solution (sepetaprost ophthalmic solution), a treatment for glaucoma and ocular hypertension with a novel mechanism of action for lowering intraocular pressure
Santen Publishes its Annual Integrated Report “Santen Report 2024”
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium
Notice of Corporate Officer Change
Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis, goes on sale in Japan
Notice of Board of Director and Corporate Auditor Nominations
Santen and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis
Santen and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL
Santen Positioned for Further Growth in China Following Completion of Santen Vision Park
Santen obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis
Santen Announces Change of Representative Director of the Board
Notice of Corporate Officer Changes
Eyedrops for slowing the progression of myopia: Santen files application for manufacturing and marketing approval STN1012700 / DE-127 (atropine sulfate hydrate ophthalmic solution) in Japan
Japan Approval Obtained for Ophthalmic VEGF inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL
 
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved